Conduit Pharmaceuticals Inc. (CDT) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Conduit Pharmaceuticals reported revenue of $0. Net income was -$39.2M, or -$294472.50 per diluted share. Operating activities generated -$15.6M of cash, leaving -$15.6M of free cash flow. At fiscal year end, Conduit Pharmaceuticals held $5.7M in total assets against $12.8M in total liabilities, including $1.5M of cash and equivalents.
Open the full interactive Conduit Pharmaceuticals financials → Quarterly statements, key ratios, valuation history and price charts.
Conduit Pharmaceuticals Key Stats
| Share Price | $0.45 |
|---|---|
| Market Cap | $9,594 |
| 52-Week Range | $0.45 – $26,125.00 |
| Shares Outstanding | 21,320 (basic, 2026 Q2) |
Conduit Pharmaceuticals Income Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Operating Income | -$1.2M | -$5.3M | -$15.4M | -$36.8M |
| Pre-Tax Income | $773,501 | -$535,000 | -$17.8M | -$39.2M |
| Income Tax | $374,862 | — | — | — |
| Net Income | $398,639 | -$535,000 | -$17.8M | -$39.2M |
| Diluted EPS | — | -$6750000.00 | -$15397500.00 | -$294472.50 |
Conduit Pharmaceuticals Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$7.1M | -$20.9M | -$4.1M | -$4.6M |
| Diluted EPS | -$82250.00 | -$628.59 | -$1390.00 | -$217.75 |
Conduit Pharmaceuticals Balance Sheet
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash & Equivalents | $345,777 | $4.2M | $554,000 | $1.5M |
| Current Assets | $646,639 | $5.7M | $2.7M | $4.4M |
| Total Assets | $137.5M | $7.2M | $4.2M | $5.7M |
| Current Liabilities | $417,975 | $1.8M | $10.7M | $12.8M |
| Total Long-Term Debt | — | $200,000 | $1.0M | — |
| Total Liabilities | $5.0M | $7.7M | $11.0M | $12.8M |
| Shareholders' Equity | -$4.3M | -$457,000 | -$6.8M | -$7.2M |
Conduit Pharmaceuticals Cash Flow Statement
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Cash From Operations | -$1.3M | -$7.7M | -$9.7M | -$15.6M |
| Cash From Investing | -$134.9M | $725,000 | -$43,000 | -$808,000 |
| Cash From Financing | $136.5M | $10.9M | $6.1M | $17.4M |
| Free Cash Flow | — | -$7.7M | -$9.8M | -$15.6M |
Figures from Conduit Pharmaceuticals' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Conduit Pharmaceuticals financials page for every line item.
Conduit Pharmaceuticals Company Profile
| Ticker | CDT |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Naples, Florida |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001896212 |
Frequently Asked Questions
What was Conduit Pharmaceuticals' revenue in fiscal 2025?
Conduit Pharmaceuticals (CDT) reported revenue of $0 for fiscal 2025.
What is Conduit Pharmaceuticals' annual revenue history?
Conduit Pharmaceuticals' annual revenue by fiscal year: 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was Conduit Pharmaceuticals' net income in fiscal 2025?
Conduit Pharmaceuticals reported net income of -$39.2M for fiscal 2025.
What was Conduit Pharmaceuticals' earnings per share (EPS) in fiscal 2025?
Conduit Pharmaceuticals' diluted EPS was -$294472.50 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Conduit Pharmaceuticals generate in fiscal 2025?
Conduit Pharmaceuticals generated -$15.6M of free cash flow in fiscal 2025.
What was Conduit Pharmaceuticals' revenue last quarter?
In its most recent reported quarter (2026 Q2), Conduit Pharmaceuticals reported revenue of $0.
How many shares of Conduit Pharmaceuticals are outstanding?
Conduit Pharmaceuticals reported a weighted average of 21,320 basic shares outstanding in 2026 Q2.
What is Conduit Pharmaceuticals' market cap?
Based on its latest closing price, Conduit Pharmaceuticals (CDT) has a market capitalization of about $9,594.
When does Conduit Pharmaceuticals' fiscal year end?
Conduit Pharmaceuticals' fiscal year end, as registered with the SEC, is December 31.
Where is Conduit Pharmaceuticals headquartered?
Conduit Pharmaceuticals lists its business address in Naples, Florida in its SEC filings.